Literature DB >> 12904364

Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Catherine Gaudy1, Alain Moreau, Pascal Veillon, Stephanie Temoin, Francoise Lunel, Alain Goudeau.   

Abstract

The heterogeneity of hypervariable region 1 (HVR1), located at the amino terminus of the E2 envelope, may be involved in resistance to alpha interferon (IFN-alpha) treatment. We investigated whether peculiar HVR1 domain profiles before treatment were associated with the maintenance of sensitivity or the appearance of resistance to treatment. Fifteen patients infected with hepatitis C virus genotype 1b and treated with IFN with or without ribavirin were selected. Ten responded to treatment (groups R1 and R2) and five did not (group NR). The amino acid sequences of 150 naturally occurring HVR1 variants present in the serum before therapy were compared in relation to treatment outcome. HVR1 variants from the NR group contained a constant nonantigenic amino acid segment that was not found in HVR1 variants from the R groups.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12904364      PMCID： PMC179854          DOI： 10.1128/JCM.41.8.3615-3622.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  45 in total

1.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

2.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Hepatitis C virus-like particle morphogenesis.

Authors:  Emmanuelle Blanchard; Denys Brand; Sylvie Trassard; Alain Goudeau; Philippe Roingeard
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions.

Authors:  B N Sobolev; V V Poroikov; L V Olenina; E F Kolesanova; A I Archakov
Journal:  J Viral Hepat       Date:  2000-09       Impact factor: 3.728

6.  Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.

Authors:  J M Pawlotsky; G Germanidis; P O Frainais; M Bouvier; A Soulier; M Pellerin; D Dhumeaux
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.

Authors:  X Forns; R Thimme; S Govindarajan; S U Emerson; R H Purcell; F V Chisari; J Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro.

Authors:  Y H Zhou; Y K Shimizu; M Esumi
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

9.  A model for the hepatitis C virus envelope glycoprotein E2.

Authors:  A T Yagnik; A Lahm; A Meola; R M Roccasecca; B B Ercole; A Nicosia; A Tramontano
Journal:  Proteins       Date:  2000-08-15

10.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728
View more
  6 in total

1.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 2.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

3.  Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.

Authors:  Isla Humphreys; Vicki Fleming; Paolo Fabris; Joe Parker; Bodo Schulenberg; Anthony Brown; Charis Demetriou; Silvana Gaudieri; Katja Pfafferott; Michaela Lucas; Jane Collier; Kuan-Hsiang Gary Huang; Oliver G Pybus; Paul Klenerman; Eleanor Barnes
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

4.  Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.

Authors:  Madiha Akram; Muhammad Idrees; Abrar Hussain; Samia Afzal; Muhammad Ilyas; Shamail Zafar; Mahwish Aftab; Sadaf Badar; Bushra Khubaib
Journal:  Virol J       Date:  2011-05-23       Impact factor: 4.099

5.  The Transmission Route and Selection Pressure in HCV Subtype 3a and 3b Chinese Infections: Evolutionary Kinetics and Selective Force Analysis.

Authors:  Ru Xu; Xia Rong; Elihu Aranday-Cortes; Sreenu Vattipally; Joseph Hughes; John McLauchlan; Yongshui Fu
Journal:  Viruses       Date:  2022-07-11       Impact factor: 5.818

6.  Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.

Authors:  Pascal Veillon; Christopher Payan; Hélène Le Guillou-Guillemette; Catherine Gaudy; Françoise Lunel
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.